Potential role of pyridoxal-5'-phosphate phosphatase/chronopin in epilepsy.
Changes in actin dynamics and pyridoxal-5'-phosphate (PLP) metabolisms are closely related to the pathophysiological profiles of the epileptic hippocampus. Recently, it has been reported that PLP phosphatase/chronophin (PLPP/CIN) directly dephosphorylates actin-depolymerizing factor (ADF)/cofilin as well as PLP. In the present study, therefore, we have investigated whether PLPP/CIN is linked to the dynamics of actin filament assembly and the excitability in the rat hippocampus. In control animals, pyridoxine chloride (PNP) treatment increased PLPP/CIN immunoreactivity only in astrocytes, which did not affect electrophysiological properties. Following status epilepticus, the PLPP/CIN protein level increased in granule cells and reactive astrocytes. These changes in PLPP/CIN protein level showed an inverse correlation with phospho-ADF (pADF)/cofilin levels and F-actin content. These changes were also accompanied by alterations in the excitability ratio and paired-pulse inhibition. Transduction of PLPP/CIN by Tat-PLPP/CIN showed similar effects on pADF/cofilin levels, F-actin content and excitability ratio in normal animals. These findings suggest that PLPP/CIN-mediated actin dynamics may play an important role in the changes of morphological properties and excitability of the epileptic hippocampus.
Kim
Ji-Eun
JE
Department of Anatomy and Neurobiology, College of Medicine, Hallym University, Chunchon, Republic of Korea.
Kim
Dae-Won
DW
Kwak
Sung-Eun
SE
Kwon
Oh-Shin
OS
Choi
Soo-Young
SY
Kang
Tae-Cheon
TC
D008841:Actin Cytoskeleton / Q000378:metabolism; D051339:Actin Depolymerizing Factors / Q000378:metabolism; D000818:Animals; D003001:Cloning, Molecular; D004195:Disease Models, Animal; D004558:Electric Stimulation; D005071:Evoked Potentials / Q000187:drug effects / Q000528:radiation effects; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008840:Microfilament Proteins / Q000378:metabolism; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics / Q000378:metabolism*; D010862:Pilocarpine; D011736:Pyridoxine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D053422:Receptor-Interacting Protein Serine-Threonine Kinases / Q000378:metabolism; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058486:Receptors, Purinergic P2X7; D013226:Status Epilepticus / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D014803:Vitamin B Complex / Q000494:pharmacology; D018909:src Homology Domains
D051339:Actin Depolymerizing Factors; C485513:Dbnl protein, rat; D005904:Glial Fibrillary Acidic Protein; D008840:Microfilament Proteins; C546470:P2rx7 protein, rat; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D010862:Pilocarpine; D014803:Vitamin B Complex; D053422:Receptor-Interacting Protein Serine-Threonine Kinases; C027138:pyridoxine phosphate phosphatase; D010744:Phosphoric Monoester Hydrolases; D010751:Phosphopyruvate Hydratase; D011736:Pyridoxine